Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$21.94 - $26.24 $173,589 - $207,610
7,912 New
7,912 $206,000
Q2 2022

Aug 16, 2022

SELL
$26.4 - $30.54 $3,880 - $4,489
-147 Reduced 1.79%
8,079 $241,000
Q1 2022

May 16, 2022

BUY
$23.07 - $27.99 $189,773 - $230,245
8,226 New
8,226 $216,000
Q4 2021

Feb 09, 2022

SELL
$21.47 - $32.08 $171,030 - $255,549
-7,966 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$23.37 - $32.13 $36,503 - $50,187
-1,562 Reduced 16.39%
7,966 $246,000
Q2 2021

Aug 16, 2021

BUY
$18.78 - $25.15 $178,935 - $239,629
9,528 New
9,528 $234,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.9B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.